Paper Details

  1. Home
  2. Paper Details

Hepatitis B surface antigen and hepatitis B core-related antigen kinetics after adding pegylated-interferon to nucleos(t)ids analogues in hepatitis B e antigen-negative patients.

Author: BessaXavier, BroquetasTeresa, CanillasLidia, CarriónJosé A, CañeteNuria, CollSusana, Garcia-RetortilloMontserrat, HernandezJuan Jose, MicóMiquel, PuigvehíMarc, ViuAna

Clinical TrialA clinical trial is a planned study conducted on humans to evaluate the efficacy and safety of pharmaceuticals, medical devices, and treatment methods. It aims to explore the possibilities of new treatments and improve the health of patients.

Overview

Adding pegylated interferon (Peg-IFN) to nucleos(t)ids analogues (NAs) therapy led to a greater and faster decrease in hepatitis B surface antigen (HBsAg) levels in patients with HBeAg-negative chronic hepatitis B. However, side effects of Peg-IFN can limit its use in clinical practice.
Paper Details　
Original Abstract of the Article :
BACKGROUND: Hepatitis B e antigen-negative chronic hepatitis B patients under nucleos(t)ids analogues (NAs) rarely achieve hepatitis B surface antigen (HBsAg) loss. AIM: To evaluate if the addition of pegylated interferon (Peg-IFN) could decrease HBsAg and hepatitis B core-related antigen (HBcrAg) ...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7701972/

データ提供：米国国立医学図書館（NLM）

Hepatitis B: A Persistent Viral Infection

Hepatitis B, a viral infection that can cause liver damage, is a significant public health concern. This study explores the effectiveness of combining pegylated interferon (Peg-IFN) with nucleos(t)ids analogues (NAs) for treating chronic hepatitis B in patients who are no longer producing hepatitis B e antigen (HBeAg). The authors conducted a prospective, non-randomized, open-label trial, examining the impact of this combination therapy on hepatitis B surface antigen (HBsAg) and hepatitis B core-related antigen (HBcrAg) levels. Their findings suggest that adding Peg-IFN to NAs can lead to faster and greater reductions in HBsAg levels compared to NAs therapy alone.

HBsAg Levels: A Key Indicator of Treatment Success

The study highlights the potential benefits of combining Peg-IFN with NAs in treating chronic hepatitis B. The combination therapy was found to be more effective in reducing HBsAg levels, a key indicator of treatment success in hepatitis B. This suggests that combining Peg-IFN with NAs may offer a more effective approach to managing chronic hepatitis B, potentially improving long-term outcomes for patients.

Hepatitis B: A Complex Condition

Hepatitis B is a complex condition, and finding effective treatment strategies is a priority for healthcare providers. This study provides valuable insights into the potential benefits of combining different therapies, highlighting the importance of continued research and development in this area.

Dr.Camel's Conclusion

This research contributes to the ongoing efforts to develop effective therapies for chronic hepatitis B, a persistent viral infection. It highlights the potential benefits of combining Peg-IFN with NAs, offering a promising strategy for reducing viral load and improving treatment outcomes. Like a desert oasis, this research provides hope for individuals struggling with hepatitis B, offering a glimmer of potential for a healthier future.
Date :
  1. Date Completed n.d.
  2. Date Revised 2020-12-30
Further Info :

Pubmed ID

33312431

DOI: Digital Object Identifier

PMC7701972

Related Literature

Article Analysis
・Side Effects of entecavir
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.